Can tablets and VR better capture how eye disease affects daily life?

NCT ID NCT07489898

Not yet recruiting Knowledge-focused Sponsor: Nisha Nixon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

Standard eye tests often miss the real-world vision problems people face, like trouble recognizing faces or navigating in low light. This study will test new tablet and virtual reality tools in 50 adults with neurodegenerative eye diseases to see if they better capture how vision affects quality of life. The goal is to improve how future treatments are evaluated in clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to better ways of measuring vision in clinical trials, helping to develop more effective treatments for eye diseases.

What could go wrong

This is a small, early feasibility study with only 50 participants. The new tests may not prove more useful than current methods, and results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEURODEGENERATIVE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary optic neuropathy neurodegenerative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••